MX2012004317A - Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico. - Google Patents

Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico.

Info

Publication number
MX2012004317A
MX2012004317A MX2012004317A MX2012004317A MX2012004317A MX 2012004317 A MX2012004317 A MX 2012004317A MX 2012004317 A MX2012004317 A MX 2012004317A MX 2012004317 A MX2012004317 A MX 2012004317A MX 2012004317 A MX2012004317 A MX 2012004317A
Authority
MX
Mexico
Prior art keywords
azabicyclo
alpha
acetylcholine receptor
receptor ligands
nicotinic acetylcholine
Prior art date
Application number
MX2012004317A
Other languages
English (en)
Inventor
John E Macor
Dalton King
Haiquan Fang
Richard E Olson
Robert A Mate
James H Ii Cook
Ivar M Mcdonald
Nenghui Wang
Christiana I Iwuagwu
F Christopher Zusi
Matthew D Hill
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2012004317A publication Critical patent/MX2012004317A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La descripción proporciona compuestos de la Fórmula 1, que incluyen la, Ib, Ic, ó Id, incluyendo sus sales, así como composiciones y procedimientos de uso de los compuestos. Los compuestos son ligandos para el receptor nicotínico a7 y pueden ser ti1es para el tratamiento de diversos trastornos del sistema nervioso central, especialmente trastornos afectivos y neurodegenerativos (Fórmula I).
MX2012004317A 2009-10-28 2010-10-25 Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico. MX2012004317A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25578209P 2009-10-28 2009-10-28
US12/907,122 US8278320B2 (en) 2009-10-28 2010-10-19 Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
PCT/US2010/053934 WO2011056503A1 (en) 2009-10-28 2010-10-25 Azabicyclo[2.2.1] heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
MX2012004317A true MX2012004317A (es) 2012-05-08

Family

ID=43455071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004317A MX2012004317A (es) 2009-10-28 2010-10-25 Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico.

Country Status (10)

Country Link
US (1) US8278320B2 (es)
EP (1) EP2493893B1 (es)
JP (1) JP2013509413A (es)
KR (1) KR20120099059A (es)
CN (1) CN102686596A (es)
AR (1) AR078815A1 (es)
AU (1) AU2010315614A1 (es)
MX (1) MX2012004317A (es)
TW (1) TW201120048A (es)
WO (1) WO2011056503A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177024A1 (en) 2012-05-24 2013-11-28 Bristol-Myers Squibb Company QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
AU2015362790A1 (en) 2014-12-16 2017-07-20 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
RU2017145964A (ru) 2015-06-10 2019-07-10 Аксовант Сайенсиз Гмбх Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
EP3365061A4 (en) * 2015-10-20 2019-03-20 Axovant Sciences GmbH AMINOISOXAZOLIN COMPOUNDS AS AGONISTS OF ALPHA7 NICOTINE ACETYLCHOLIN RECEPTORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808433D0 (en) 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
US5053412A (en) 1990-04-10 1991-10-01 Israel Institute For Biological Research Spiro nitrogen-bridged heterocyclic compounds
IL97726A (en) 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds
EP0777671B1 (en) 1994-08-24 2000-04-26 Astra Aktiebolag Spiro-azabicyclic compounds useful in therapy
MXPA04010921A (es) 2002-05-03 2005-05-27 Israel Inst Biolog Res Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos.
GB0214596D0 (en) 2002-06-25 2002-08-07 Itw Ltd Hoses
BRPI0412382A (pt) 2003-07-08 2006-09-19 Astrazeneca Ab composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto
KR20070090922A (ko) 2004-12-15 2007-09-06 아스트라제네카 아베 니코틴성 아세틸콜린 수용체 리간드
US20070004715A1 (en) 2005-06-30 2007-01-04 Yifang Huang Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
JP2013509413A (ja) 2013-03-14
TW201120048A (en) 2011-06-16
EP2493893B1 (en) 2014-01-15
EP2493893A1 (en) 2012-09-05
AR078815A1 (es) 2011-12-07
US20110263605A1 (en) 2011-10-27
CN102686596A (zh) 2012-09-19
US8278320B2 (en) 2012-10-02
WO2011056503A1 (en) 2011-05-12
AU2010315614A1 (en) 2012-06-14
KR20120099059A (ko) 2012-09-06

Similar Documents

Publication Publication Date Title
IL208673A (en) Quinuclidine compounds ligandes for nicotinic alpha-7 acetylcholine receptor
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
TN2012000530A1 (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
ATE502939T1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten
MY148780A (en) Tricyclic compounds, compositions, and methods
MX342177B (es) Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.
TN2011000220A1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
PH12015500883A1 (en) Heteroaromatic compounds as dopamide d1 ligands
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
MX2012004317A (es) Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico.
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
TW200642690A (en) Composition for treating central nervous system disorders
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MX2010009920A (es) Compuestos de azaindol para tratamiento de trastornos del sistema nervioso central.
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
MX2010004300A (es) Ligandos de (1,4-diaza-biciclo [3,2,2]non-6-en-4-il)-heterociclil- metanona para receptores nicotinicos de acetilcolina, utiles para el tratamiento de enfermedad.
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
IN2014DN09826A (es)
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.

Legal Events

Date Code Title Description
FG Grant or registration